Our present demonstration that depending on the tumor cell type, a combination of CXCL12 and CXCL11 either allows for pro- or anti-tumor activity put caution on ongoing efforts to establish chemokine receptors as therapeutic targets in cancer [45]. Here, CXCL11 is linked to neoplasm.